Herbst Kinsky advises the biotech start-up OnceOne Research & Development GmbH from Lower Austria, which specializes in the development of innovative cancer therapies, in its series A financing round with investors such as the Austrian Research Promotion Agency (FFG), the Austria Wirtschaftsservice Gesellschaft (AWS) and two family offices in the amount of EUR 13 million.

Founded in 2018, the company aims to develop several proprietary drug modalities targeting oxMIF (oxidized Macrophage Migration Inhibitory Fac-tor) to rapidly enter clinical trials in pancreatic, colorectal, lung and ovarian cancer.

“Our company name reflects our shared ambition to use our combined drug development expertise to unlock the multiple potential of oxMIF, and the initial funding will enable us to explore this potential to provide innovative treatments for cancer indications with poor prognosis”, says Dr. Randolf Kerschbaumer, co-founder of OncoOne.

Herbst Kinsky´s transaction team was led by Philipp Kinsky supported by Georg Durstberger.